Yin Yuqin, Benowitz Larry I
Department of Neurosurgery, F.M. Kirby Neurobiology Center, Boston Children's Hospital, CLS 13030-15, 3 Blackfan Circle, 300 Longwood Ave., Boston, MA, 02115, USA.
Department of Neurosurgery, Harvard Medical School, Boston, MA, 02115, USA.
Methods Mol Biol. 2018;1695:187-205. doi: 10.1007/978-1-4939-7407-8_16.
Glaucoma is marked by a progressive degeneration of the optic nerve and delayed loss of retinal ganglion cells (RGCs), the projection neurons of the eye. Because RGCs are not replaced and because surviving RGCs cannot regenerate their axons, the visual loss in glaucoma is largely irreversible. Here, we describe methods to evaluate treatments that may be beneficial for treating glaucoma using in vitro cell culture models (immunopanning to isolate neonatal RGCs, dissociated mature retinal neurons, retinal explants) and in vivo models that test potential treatments or investigate underlying molecular mechanisms in an intact system. Potentially, use of these models can help investigators continue to improve treatments to preserve RGCs and restore visual function in patients with glaucoma.
青光眼的特征是视神经进行性退化以及视网膜神经节细胞（RGCs）延迟丧失，RGCs是眼睛的投射神经元。由于RGCs无法被替代，且存活的RGCs不能再生其轴突，因此青光眼导致的视力丧失在很大程度上是不可逆的。在这里，我们描述了使用体外细胞培养模型（免疫淘选以分离新生RGCs、解离的成熟视网膜神经元、视网膜外植体）和体内模型来评估可能有益于治疗青光眼的方法，这些体内模型用于测试潜在治疗方法或在完整系统中研究潜在分子机制。这些模型的使用有可能帮助研究人员不断改进治疗方法，以保护青光眼患者的RGCs并恢复其视觉功能。
